ENPP1/CD203a-targeting heavy-chain antibody reveals cell-specific expression on human immune cells

• DOI: 10.1007/s00018-024-05539-y
• Publication Date: 2024-12-18T16:59:28Z
• Authors: Hannah Lorenz; Stephan Menzel; Nataliia Roshchyna; Birte Albrecht; Anna Josephine Ge...; Enja Schneider; Friedrich Haag; Björn Rissiek; Ralf Oheim; Friedrich Koch-Nolte; Riekje Winzer; Eva Tolosa
• Keywords: 0301 basic medicine; 0303 health sciences; Original Article

AbstractENPP1/CD203a is a membrane-bound ectonucleotidase capable of hydrolyzing ATP, cGAMP and other substrates. Its enzymatic activity plays an important role in the balance of extracellular adenine nucleotides and the modulation of purinergic signaling, in soft tissue calcification, and in the regulation of the cGAS/STING pathway. However, a detailed analysis of ENPP1 surface expression on human immune cells has not been performed. Here, we selected VHH domains from human ENPP1-immunized alpacas to generate heavy-chain antibodies targeting ENPP1, and analyzed cell surface expression on all circulating immune cell subsets using flow cytometry. We find high expression of ENPP1 in CD141high conventional dendritic cells (cDC1), while ENPP1 was not detectable on other dendritic cells and monocytes. In the lymphocytic compartment, only CD56bright natural killer cells and mucosal-associated invariant T cells (MAIT) express ENPP1. In contrast, all other T cell subpopulations, CD56dim natural killer cells and B lymphocytes do not or only minimally express ENPP1. In summary, we describe highly cell type-specific expression of ENPP1 in the immune system using a newly generated heavy-chain antibody. This reagent will help to decipher the function of ENPP1 in the regulation of the immune response, allow a quick identification of ENPP1-deficiency and of ENPP1-positive tumors, and constitutes the basis for targeted anti-tumor intervention.